The suppressive capacity of regulatory T cells (Tregs) has been extensively studied and is well established for many diseases. The expansion, accumulation, and activation of Tregs in viral infections are of major interest in order to find ways to alter Treg functions for therapeutic benefit. Tregs are able to dampen effector T cell responses to viral infections and thereby contribute to the establishment of a chronic infection. In the Friend retrovirus (FV) mouse model, Tregs are known to expand in all infected organs. To better understand the characteristics of these Treg populations, their phenotype was analyzed in detail. During acute FV-infection, Tregs became activated in the spleen and bone marrow, as indicated by various T cell activation markers, such as CD43 and CD103. Interestingly, Tregs in the bone marrow, which contains the highest viral loads during acute infection, displayed greater levels of activation than Tregs from the spleen. Treg expansion was driven by proliferation but no FV-specific Tregs could be detected. Activated Tregs in FV-infection did not produce Granzyme B (GzmB) or tumor necrosis factor α (TNFα), which are thought to be a potential mechanism for their suppressive activity. Furthermore, Tregs expressed inhibitory markers, such as TIM3, PD-1 and PD-L1. Blocking TIM3 and PD-L1 with antibodies during chronic FV-infection increased the numbers of activated Tregs. These data may have important implications for the understanding of Treg functions during chronic viral infections.
Citation: Jara J. Joedicke, Kirsten K. Dietze, Gennadiy Zelinskyy, Ulf Dittmer. The phenotype and activation status of regulatory T cells during Friend retrovirus infection[J]. VIROLOGICA SINICA, 2014, 29 (1): 48-60 https://doi.org/10.1007/s12250-014-3396-z
Received: 18 October, 2013; Accepted: 3 January 2014; Published: 20 January 2014
Copyright: © WIV, CAS and Springer-Verlag Berlin Heidelberg 2014
Data Availability: All relevant data are within the paper and its Supporting Information files.
Corresponding author: Ulf Dittmer Phone: +49-2017233693, Fax: +49-2017235929, E-mail: firstname.lastname@example.org.
Regulatory T cells (Tregs) have been described to have important functions in the control of the immune system (Sakaguchi S et al, . 1995). On one hand, their suppressive potential is important in the prevention of autoimmune diseases (Kohm A P et al, . 2002)as well as other over-shooting immune reactions. This also plays a role in preventing immunopathology during viral infections (Mills K H, 2004). On the other hand, Treg can play a detrimental role by preventing sufficient anti-tumor responses (Wang H Y et al. 2004; Wang H Y et al. 2004) or immune responses against a pathogen (Mills K H, 2004). The latter scenario can contribute to the establishment of a chronic infection. This has been described for certain viruses such as hepatitis B virus, hepatitis C virus (Furuichi Y et al, . 2005; Manigold T et al, . 2007; Yang J H et al, . 2006) and human immunodeficiency virus-1 (Chevalier M F et al, . 2013; Nilsson J et al, . 2006).
Mice infected with Friend retrovirus (FV) are a useful model for retroviral infections in vivo, and serve as a good system for assessing the contribution of Tregs to chronic infection. We and others have already shown that the cytotoxic CD8+ T cell (CTL) response is suppressed by Tregs in the chronic phase of FV-infection, which contributes to the establishment of a chronic infection (Dittmer U et al, . 2004; Iwashiro M et al, . 2001). In mice, Tregs can be distinguished from conventional CD4+ T helper cells (Tcons) by the expression of the transcription factor forkhead box P3 (Foxp3), which is important for Treg development, maintenance and suppressive activity (Fontenot J D et al, . 2005). We have shown that Foxp3+ Tregs expand significantly during FV-infection in all infected organs (Zelinskyy G et al, . 2009). High viral titers can be specifically detected in the bone marrow and spleen. Interestingly, the infection leads to a massive immune cell infiltration into these organs to combat the virus.
During FV-infection a polyclonal population of Tregs expands; however, a distinct population of T cell receptor (TCR)-Vβ5+ Tregs was recently shown to exhibit disproportionally greater expansion than the bulk of TCR-Vβ5- Tregs (Myers L et al, . 2013). This expansion was caused by the constitutively expressed mouse mammary tumor endogenous retrovirus-9 (mtv-9) superantigen (Sag). It has been described that this Sag binds specifically to the Vβ5+ chain and causes a stimulation of T cells (Choi Y et al, . 1991; Woodland D et al, . 1990). Myers et al. used the FV-model and observed that only Vβ5+ Tregs responded with a disproportionate expansion during the infection, whereas conventional Vβ5+ T cells and Vβ5+CD8+ T cells were not influenced (unpublished observations). Moreover, we showed that the effector CD8+ T cell response is an important factor in triggering this Vβ5+ Treg expansion (Myers L et al, . 2013). Interestingly, the data presented herein demonstrated that the activation of Vβ5+ Tregs was distinct from the bulk of the expanding Tregs during FV-infection, which were Vβ5-. It was shown that the Vβ5+ Tregs exhibited the phenotype of highly activated, short-lived effector cells, whereas Vβ5- Tregs showed less activation and differentiation during FV-infection. Although the Vβ5+ Tregs required tumor necrosis factor α (TNFα) for their expansion, the bulk population of Vβ5- Tregs was strictly dependent on interleukin-2 (IL-2).
We set out to investigate the role of Tregs during acute and chronic FV-infection in mice by characterizing their activation profile and their functional properties. Our data have highlighted that expanding Tregs become activated in the bone marrow and spleen during acute infection, with Vβ5+ Tregs being more activated than Vβ5- Tregs. Tregs were not virus-specific and did not produce cytotoxic molecules, such as Granzyme B (GzmB), or the pro-inflammatory cytokine TNFα. The expansion of Vβ5- Tregs could be triggered by virus-specific CD4+ T cells producing IL-2. Finally, we assessed the expression of inhibitory markers on Tregs during acute FV-infection: blocking of two of these markers, T cell immunoglobulin and mucin protein 3 (TIM3) and programmed death ligand 1 (PD-L1), during chronic infection led to enhanced Treg expansion and activation. This could have important implications for therapies targeting inhibitory markers to enhance T cell responses during infection.
Inbred C57BL/6 (B6), DEREG (DEpletion of REGulatory T cells) and EVa3 mice (unpublished mouse strain) kindly provided by George Kassiotis) were maintained at the mouse facility in the University Hospital Essen under pathogen-free conditions. EVa3 mice are doubly transgenic for the TCRα and TCRβ chains of the env122-141-specific CD4+ T cell clone H18 (Young G R et al, . 2012), and will be described in detail elsewhere. Experiments were performed using mice with the relevant FV-resistance genotype; H-2b/b, Fv1b/b, Fv2r/r (B6), or transgenic mice backcrossed on the B6 background. All studies were carried out using female mice aged 8 to 12 weeks at the start of the experiment. All animal experiments were performed in strict accordance with the German regulations of the Society for Laboratory Animal Science (GV-SOLAS) and the European Health Law of the Federation of Laboratory Animal Science Associations (FELASA). Protocols were approved by the North Rhine-Westphalia State Agency for Nature, Environment and Consumer Protection (LANUV) (Permit number: G 1208/11).
Virus stock and infection
The FV stock used for all viral infections was a complex containing the B-tropic Friend murine leukemia helper virus (F-MuLV) and the polycythemia-inducing spleen focus-forming virus (SFFV) (Lilly F et al, . 1973). The virus stock was prepared as previously described (Zelinskyy G et al, . 2009). For acute infections, mice were injected intravenously (i.v.) with 20, 000 SFFU of FV. For chronic FV-infections, mice were infected i.v. with 60, 000 SFFU of FV and additionally with 2×105 infectious center assay units of F-MuLV to enhance the chronic viral infection. The virus stocks used in this study did not contain lactate dehydrogenase-elevating virus.
Cell surface and intracellular staining using flow cytometry
For cell surface staining, 3-6×106 spleen or bone marrow cells were re-suspended in FACS buffer containing the required antibodies and stained for 30 min at 4 ℃. The following antibodies were used for the surface staining: α-CD4 (GK1.5, eBioscience), α-CD8 (53-6.7, eBioscience), α-CD25 (PC61.5, BD Bioscience), α-CD69 (H1.2F3, eBioscience), α-CD43 (1B11, BioLegend), MHC class Ⅱ tetramer (I-Ab-estricted FV-specific CD4+ T cell epitope H19-Env, Beckman and Coulter), α-CD11b (M1/70, BD Bioscience), α-CD45.1 (A20, eBioscience), α-Vβ5 (MR9-4, eBioscience), α-TIM3 (8B.2C12, R & D Systems), α-PD-1 (29F.1A12, eBioscience) and α-PD-L1 (10F.9G2, eBioscience). For intracellular cytokine staining, the cells were stimulated for 5 hours at 37 ℃ with 10 µg/mL plate-coated α-CD3 and 2 µg/mL soluble α-CD28 antibodies in the presence of 2 µg/mL brefeldin A. For other intracellular stains, the cells were not stimulated before staining. For intracellular staining protocols, the Foxp3/transcription factor staining buffer set from eBioscience or the BD Cytofix/Cytoperm kit (BD Biosciences) was used. The procedure was carried out according to the manufacturer's instructions. For intracellular staining, the following antibodies were used: α-Foxp3 (FJK-16s, eBioscience), α-Helios (ssF6, BioLegend), α-Ki67 (SolA15, eBioscience), α-BrdU (BU20A, BD Bioscience), α-IL-2 (JES6-5H4, eBioscience), α-TNFα (MP6-XT22, eBioscience), and α-GzmB (GB11, Invitrogen). Flow cytometry data were acquired on an LSRII flow cytometer (BD Biosciences) and the analysis was performed using FlowJo (Treestar) analysis software, where only single live cells were used for analysis.
Bromodeoxyuridine (BrdU) labeling of mouse cells via drinking water and BrdU staining
Mice were supplied with 50 mL of water containing 0.8 mg/mL BrdU for three days (refreshed daily) before sacrificing. BrdU incorporation was determined using the BrdU flow kit (BD Biosciences) protocol, as previously described (Zelinskyy G et al, . 2009).
Antibody treatment of infected mice
For in vivo blockage of the programmed death-1 (PD-1) pathway, 200 µg of rat α-mouse PD-L1 mAb (10F.9G2; BioXCell) was administered four times via the intra-peritoneal (i.p.) route in a three-day interval. To block the TIM-3 pathway, 100 µg of rat α-i-mouse TIM-3 mAb (RMT3-23; BioXCell) were administered four times i.p. in a two-day interval. Both treatments were started 6 weeks post infection.
CD4+ T cell transfer
Magnetic bead separation of CD4+ T cells from the lymph nodes and spleen of na ve EVa3 transgenic (EVa3tg) or EVa3 wild type (EVa3wt) mice was performed using the CD4+ T cell isolation kit Ⅱ (Miltenyi Biotec) according to the manufacturer's instructions. The purity of isolated CD4+ T cells assessed by FACS was greater than 80%. 5×106 cells were then transferred into infected mice (4 days post infection (dpi)) by i.v. injection and the mice were sacrificed at 7 dpi.
Statistical analysis and data presentation were performed using GraphPad Prism software. All data sets were first tested for normality using the D'Agostino and Pearson omnibus normality test. Data were then assessed using either parametric one-way analysis of variance (ANOVA) or non-parametric Kruskal-Wallis test. Statistical significances were calculated using the Bonferroni post-test (parametric) or the Dunn's post-test (non-parametric) assessment methods. When only two groups were analyzed, data was tested using a parametric or non-parametric Student's t-test.
Activated Tregs expand in the bone marrow and the spleen during FV-infection and remain at elevated levels during chronic infection
The Ikaros transcription factor Helios was described as a marker for natural Tregs (nTregs) (Sugimoto N et al., 2006; Thornton A M et al., 2010), although it is now believed to be more of an activation marker of Tregs (Gottschalk R A et al., 2012). Tregs have been shown to expand in several organs of FV-infected mice (Akimova T et al., 2011; Verhagen J et al., 2010). To compare the expansion kinetics of activated Tregs in two organs after FV-infection (Zelinskyy G et al, . 2009), the numbers of CD4+Foxp3+Helios+ T cells in the bone marrow and the spleen were investigated. Activated Tregs expanded in both organs during the acute infection, with peak expansion at 12 to 14 dpi. Elevated levels of activated Tregs remained in the late acute (21 dpi) and chronic (40 dpi) phases of virus infection (Figure 1). As expected, much greater numbers of activated Tregs were present in the spleen than in the bone marrow. Interestingly, we observed a much higher Treg to Tcon ratio in the bone marrow than in the spleen (38.5±6% for the bone marrow vs. 17.7±5% in the spleen at peak expansion). In conclusion, Tregs become activated during FV-infection and undergo a large expansion in the spleen and bone marrow, and the level of activated Tregs remains elevated throughout chronic FV-infection in the spleen.
Treg activation is high in FV-infected organs
Recently we described a special subset of Tregs that expands during FV-infection (Myers L et al, . 2013). These Tregs are Vβ5+, specific for the endogenous Sag of mtv-9 and expand disproportionally more than Tregs not expressing Vβ5 (Myers L et al, . 2013). This Vβ5+ Treg subset also shows the phenotype of terminally differentiated, short-lived effector cells. To assess these two Treg populations in more detail, expression analysis of a set of activation markers was performed.
CD69 is an early activation marker of T and NK cells and becomes up-regulated when these cells are activated. A higher percentage of Tregs were positive for CD69 compared with Tcons in both organs (Figure 2A). Interestingly, in the bone marrow a higher percentage of Vβ5+ Tregs positive for CD69 was detected, compared to Vβ5- Tregs, whereas no significant differences were seen in the spleen for this marker (Figure 2A). The activation-induced glycosylated isoform of CD43 was also expressed on both Tregs and Tcons, with a higher percentage of CD43+ Tregs than CD43+ Tcons, but this was only observed in the spleen (Figure 2B). Similar results were obtained for CD103 expression. CD103 is an integrin protein important for T cell homing to intestinal sites. Tregs of FV-infected mice showed a higher percentage of CD103 when compared to Tcons (Figure 2C). Interestingly, the expression of CD43 and CD103 was elevated on Vβ5+ Tregs compared to Vβ5- Tregs in both organs, highlighting the increased activation status of Vβ5+ Tregs. It is noteworthy that the activation level of Tregs measured by the expression of CD69, CD43, and CD103 was higher in the bone marrow than in the spleen during acute FV-infection (Figure 2A-C, compare left (spleen) to right (bone marrow) for Vβ5+ and Vβ5- Treg subsets from infected mice). Other activation markers that are frequently used to characterize activated Tcons, such as CD44 or CD62L, were not differently expressed between Tregs from na ve mice and from FV-infected mice (data not shown). Thus, these markers are not useful to define activated Tregs in FV-infection.
Next, the proliferation profile and expression of Bcl2 (B-cell lymphoma 2), as a pro-apoptotic marker, in Tregs was investigated. Mice were fed with BrdU, and the incorporation of BrdU into the DNA of dividing cells was assessed. Tregs had undergone more proliferation than Tcons in both organs after FV-infection, with a higher percentage of dividing cells for Vβ5+ Tregs compared to Vβ5- Tregs (Figure 3A and B). Interestingly, the frequency of BrdU+ Tregs was higher in the bone marrow than in the spleen, reflecting the higher immune cell activation in this organ. Similar results were obtained for Ki67, a marker only expressed during the active stages of the cell cycle (data not shown). When stained for the anti-apoptotic marker, Bcl2, it was observed that activated Tregs and Tcons down-regulated Bcl2 in the spleen after FV-infection (data not shown). This implies a higher susceptibility of activated T cells to apoptosis in the spleen of infected mice. Taken together, Tregs show higher activation and proliferation than Tcons in the bone marrow and spleen, with Vβ5+ Tregs displaying the most activated phenotype.
Tregs expanding during FV-infection are not specific for an immunodominant CD4+ T cell epitope
It is has been reported for some virus infections that virus-specific Tregs exist, although their numbers are quite low (Bedoya F et al, . 2013; Ebinuma H et al, . 2008; Piersma S J et al, . 2010). We therefore analyzed whether or not the expanding Tregs during FV-infection are virus-specific. We made use of the MHC class Ⅱ tetramer technology, utilizing an immunodominant FV-specific CD4+ T cell epitope (I-Ab-restricted CD4+ T cell FV H19-Env epitope). As bone marrow Tregs showed the highest level of activation, in comparison to splenic Tregs, Foxp3+ bone marrow Tregs from na ve and infected Foxp3 reporter mice (GFP+) were stained with MHC class Ⅱ tetramers. We were unable to detect any MHC class Ⅱ tetramer+ Tregs in na ve as well as infected mice, whereas MHC class Ⅱ tetramer+ Tcons were readily detectable in acutely infected mice (Figure 4A and B). In conclusion, it was found that the Treg population expanding during FV-infection is non-specific against an immunodominant epitope.
The expansion of Vβ5- Tregs is driven by virus-pecific CD4+ Tcons
We have previously shown that Vβ5+ Treg expansion is IL-2 independent, whereas Vβ5- Tregs require IL-2 (Myers L et al, . 2013). To determine whether this IL-2 is produced by Tcons during acute FV-infection, we transferred CD4+ T cells from FV-specific CD4+ TCR transgenic (tg) or wildtype (wt) EVa3 mice into FV-infected animals. The transfer was carried out at 4 dpi and the analysis at 7 dpi, before Tregs had expanded, to ensure that only transferred but not endogenous CD4+ T cells trigger Treg expansion. In infected recipient mice, the CD4+ TCR tg cells recognized their cognate FV-antigen and expanded in the spleen, whereas CD4+ T cells from non-tg littermates did not expand (Figure 5A). The CD4+ TCR tg cells mediated an expansion of endogenous Vβ5- Tregs, whereas the population of endogenous Vβ5+ Tregs was unaltered (Figure 5B). Furthermore, TCR tg CD4+ T cells produced IL-2 after transfer, in contrast to transferred CD4+ cells from non-transgenic EVa3 wildtype mice (Figure 5C). The expansion of Vβ5- Tregs was most likely to be a direct effect of the transferred TCR tg CD4+ T cells, as no changes in IL-2 production in the endogenous population of CD4+ or CD8+ T cells were observed after transfer (Figure 5D and E). In summary, the results suggest that the IL-2 that is required for the expansion of the Vβ5- Tregs is produced by virus-specific Tcons.
Tregs do not produce cytokines or cytotoxic molecules during acute FV-infection
To further characterize Treg function during FV-infection, the production of GzmB and the cytokine TNFα was investigated in Tregs from the bone marrow. The bone marrow was chosen, as this organ contains T cells with the highest levels of activation during FV-infection (Figure 2 and data not shown). Tregs are able to secrete GzmB (Akhmetzyanova I et al, . 2013). During the acute FV-infection CD8+ T cells are potent producers of GzmB (Zelinskyy G et al., 2006), whereas Tcons only showed a minor increase in GzmB production (Figure 6A). In contrast, Tregs did not produce any GzmB during acute FV-infection (Figure 6A). To analyze whether Tregs produce a predominant pro-inflammatory cytokine during acute FV-infection, intracellular TNFα staining was performed. High numbers of CD8+ T cells and CD4+ Tcons producing TNFα were detected during FV-infection (Figure 6B). However, Tregs did not stain positive for TNFα during FV-infection (Figure 6B). Thus, in contrast to effector T cells, Tregs do not produce pro-inflammatory cytokines or cytotoxic molecules at peak Treg expansion and activation.
Tregs up-regulate inhibitory receptors during acute FV-infection
The expression of inhibitory molecules on T cells such as TIM3, PD-1 and PD-L1, are known to mediate immunosuppressive functions. PD-1 is a negative regulator of T cell proliferation and activation and mediates suppressive functions after binding to its ligands PD-L1 or PD-L2 (Barber D L et al, . 2006; Blackburn S D et al, . 2009). TIM3 is an inhibitory molecule mainly observed on Tcons, which mediates cell death upon ligation (Jones R B et al, . 2008). Interestingly, Tregs expressed three of these inhibitory markers on their surface (PD-L2 was not tested), and even showed an up-regulation during acute FV-infection, a phenotype which was also observed for Tcons (Figure 7A-C). Furthermore, it was found that the frequency of Tregs and Tcons expressing these markers was enhanced in the bone marrow compared to the spleen during acute FV-infection (Figure 7A-C). Therefore, similar to effector T cells, Tregs up-regulate inhibitory receptors and ligands during acute FV-infection.
Blocking PD-L1 and TIM3 during the chronic phase of FV-infection enhances Treg expansion and activation
CD8+ T cells become dysfunctional during the chronic phase of FV-infection and express inhibitory markers, such as TIM3 and PD-1. The treatment of chronically infected mice with α-PD-L1 and α-TIM3 has been shown to have beneficial effects on CD8+ T cell responses (Dietze K K et al, . 2013), which may help to reduce chronic viral loads. However, the effect of this treatment on Tregs has not been addressed so far, although both PD-1 and TIM3 were expressed on Tregs (Figure 7A and B). Mice were chronically infected with FV followed by treatment with α-PD-L1 and α-TIM3 antibodies at 6 weeks post infection. Immune responses in the spleen were investigated based on the earlier observation that in chronic infection the virus loads were higher in the spleen than the bone marrow (Zelinskyy G et al, . 2009). Treg numbers significantly increased when mice were treated with α-PDL-1 or α-PDL-1 plus α-TIM3 (Figure 8A). The numbers of Tregs expressing CD43 also increased during the treatment with α-PD-L1 and α-PD-L1 plus α-TIM3 antibodies (Figure 8B). This suggests that inhibitory receptors influence not only effector T cells functions but also the activation and expansion of Tregs.
In this study, we have shown that Tregs expand in the spleen and bone marrow during acute FV-infection and that the cells displayed an activated phenotype with significant proliferation. Interestingly, the bone marrow contained a much higher ratio of Tregs to Tcons than the spleen during acute infection, but the overall number of Tregs present in the bone marrow was much lower than in the spleen. The activation of Tregs after virus infections has been described, but the mechanisms of activation are not fully understood (Bedoya F et al, . 2013; Presicce P et al., 2011; Sanchez A M et al, . 2012). Recently, we described two subsets of activated Tregs expanding during FV-infection, Vβ5+ and Vβ5- Tregs (Myers L et al., 2013). Vβ5+ Tregs are mtv-9 Sag specific and expand in response to TNFα produced by effector CD8+ T cells rather than to virus antigen. Another population, Vβ5- Tregs, is not Sag specific and independent of TNFα and CD8+ T cells. In this study, we confirmed that FV-induced Tregs are not FV-specific, indicating that viral antigen does not drive their proliferation. However, the Vβ5- Treg subset requires IL-2 for their activ ation and proliferation. IL-2 is an important survival factor for Tregs and other T cells, but is not itself produced by Tregs (Barron L et al, . 2010; Malek T R, 2003; Scheffold A et al, . 2005). This study shows that the IL-2 driving the Vβ5- Treg activation and expansion is produced by virus-specific CD4+ Tcons, which respond to the infection. This IL-2 production has beneficial effects for the anti-viral immune response, on the one side, as it is an important survival factor for Tcons and CD8+ T cells (Kryworuchko M et al, . 2006). On the other side it also drives activation and expansion of Tregs, which in turn suppress anti-viral immune responses. Furthermore, it has been described that IL-2, IL-2Rα, and IL-2Rβ deficient mice develop a strong lymphoproliferative syndrome and suffer from severe autoimmunity because of impaired Treg responses (Sadlack B et al, . 1993; Suzuki H et al, . 1997; Willerford D M et al, . 1995) rather than immune dysfunction due to activation deficiency of Tcons. In conclusion, IL-2 is a factor that induces a fine balance between immune activation and suppression during an ongoing infection. Thus, blocking IL-2 during infectious diseases might be an effective therapeutic approach to inhibit activation and expansion of Tregs.
Comparison of the Treg subsets, with regard to their activation in the two organs, revealed stark differences. Vβ5- Tregs from infected mice appeared to be less activated than Vβ5+ Tregs from infected mice in both organs when the expression of CD43 and CD103 were quantified. In the spleen, Vβ5+ Tregs proliferated more than Vβ5- Tregs from infected animals. The stark activation of Vβ5+ Tregs was shown in an LCMV infection model (Punkosdy G A et al, . 2011) and when the FV-model was used (Myers L et al, . 2013). Sag stimulation has been shown to induce Tregs and to activate them (Taylor A L et al, . 2010). This could provide an explanation for the high activation of Vβ5+ Tregs. Tregs expanding in FV-infection are nTregs (Antunes I et al, . 2008; Myers L et al, . 2013)and not specific for an immunodominant epitope of CD4+ Tcons in FV-infection. Furthermore, Treg activation was higher than activation of Tcons in both organs, except for CD43 in the bone marrow. Tregs also showed higher proliferation compared to Tcons in FV-infected mice. Interestingly, these effects were already seen when na ve Tregs and Tcons were compared (data not shown), hinting towards a pre-activation of Tregs. Indeed, nTregs, which directly arise from the thymus, are self-reactive and recognize self-antigens (Cabarrocas J et al, . 2006; Coquet J M et al, . 2013; Coutinho A et al, . 2005; Leavy O, 2013). Resulting from this, nTregs are constantly exposed to their specific antigen in circulation and thus nTregs are activated at a low level (Killebrew J R et al, . 2011). In conclusion, activated and expanded Tregs are not specific for viral proteins during acute FV-infection. Vβ5+ Tregs are mtv-9 Sag specific and become activated via TCR stimulation mediated by Sag cross-linking MHC Ⅱ and the TCR-Vβ5 chain (Woodland D L et al, . 1993). As a second signal for proliferation and differentiation, these cells require TNFα (Myers L et al, . 2013). By contrast, the specificity of the Vβ5- Treg subset remains to be defined. These cells do receive a TCR signal of unknown origin (unpublished observations) and need IL-2 as a secondary signal for full activation and expansion.
Thus far, no mechanism for Treg-induced immune suppression during FV-infection has been shown, but a few possibilities can be excluded. Tregs in FV-infection do not mediate suppression via the secretion of IL10 (Dittmer U et al, . 2004; Iwashiro M et al, . 2001), and only minor effects were observed when transforming growth factor β (TGF-β) was blocked in an in vitro assay system (Robertson S J et al, . 2006). However, Robertson et al. (2006) showed that Tregs suppress FV-specific CD8+ T cells in an in vitro system in a cell-contact dependent, APC-independent manner, without IL-10 and TGF-β being involved. The cytotoxic T-lymphocyte antigen 4 appears to play some role for Treg-mediated suppression (Iwashiro M et al, . 2001). All these effects were shown in an in vitro assay and cannot directly be extrapolated to the FV-infection model, since the behavior of Tregs in vivo can be very different from that in vitro. GzmB is a serine protease that can, with the help of perforin, kill cells in close proximity and has been shown to be produced by Tregs in an FV in vivo tumor model (Akhmetzyanova I et al, . 2013). CD8+ T cells are potent producers of GzmB during FV-infection (Zelinskyy G et al, . 2006) and Tcons are able to produce low amounts of this cytokine, although Tregs do not. TNFα, a cytokine that can mediate apoptosis in adjacent cells, is also produced by CD8+ T cells and Tcons during FV-infection, but again not by Tregs.
Finally, we investigated the expression of inhibitory markers on Tregs during acute FV-infection. An up-regulation for all the markers investigated (TIM3, PD-1 and PD-L1) was seen for both Tregs and Tcons. The detection of elevated levels of these inhibitory molecules on Tregs argues towards a role in Treg biology. In a systemic model of murine acute myeloid leukemia, Treg-mediated suppression of CD8+ T cells was dependent on the expression of PD-1 on Tregs (Zhou Q et al, . 2010). Furthermore, Tregs that express PD-1 and TIM3 are highly suppressive (Sakuishi K et al, . 2013). Interestingly, Francisco et al. (2009) showed that PD-L1 is important for the function of induced Tregs (Francisco L M et al, . 2009). We have investigated the effect of antibodies directed to TIM3 and PD-L1 to use in chronic FV-infection. Treatments with these antibodies have been described to boost CD8+ T cell responses and lower viral titers (Barber D L et al, . 2006; Li W et al, . 2011; Palmer B E et al, . 2013). When mice were treated with the two blocking antibodies, Treg numbers were increased and elevated numbers of activated Tregs were observed. These Tregs are possibly memory Tregs, which can be re-activated when CD8+ and CD4+ Tcons become re-activated during antibody treatment. Sanchez et al. have shown that memory Tregs exist in viral infections and expand rapidly upon secondary challenge (Sanchez A M et al, . 2012). The blocking of two molecules which are associated with inhibitory functions on CD8+ T cells and Tcons is likely to have a similar effect on Tregs as for other subsets of T cells. Consequently, Tregs that might be restricted in their activation due to TIM3 and PD-1 expression during chronic FV-infection can be further stimulated when PD-L1 and TIM3 are blocked. Whether the expanding Tregs are more suppressive than Tregs from untreated mice remains to be investigated. The data presented here have shown that inhibitory molecules expressed by Tregs and other T cells could make novel targets for therapeutics, aiming at re-awakening the immune system during chronic viral infections and thereby reducing chronic viral titers. However, the activation of Tregs has to be considered as a potential threat to Tcon and CD8+ T cell activation and therapies have to be designed according to this insight.
This work was supported by the German Research Association (DFG) Transregio 60 project B4 and DI 1914/1-1 (www.dfg.de) as well as a graduate school grant given to JJJ as part of the GK1045 funding provided by the DFG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
JJJ performed the experiments, collected and analyzed the data and wrote the paper. KKD performed the experiments and collected the data. GZ collected and analyzed the data. UD conceived and designed the study and wrote the paper. All authors read and approved the final manuscript.
- . Akhmetzyanova I, Zelinskyy G, Schimmer S, Brandau S, Altenhoff P, Sparwasser T, Dittmer U. 2013. Tumor-specific cd4+ t cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory t cells. Cancer Immunol Immun: CII, 62: 257-271.
- . Akimova T, Beier U H, Wang L, Levine M H, Hancock W W. 2011. Helios expression is a marker of t cell activation and proliferation. PloS One, 6: e24226.
- . Alatrakchi N, Koziel M. 2009. Regulatory t cells and viral liver disease. J Viral Hepatitis, 16: 223-229.
- . Antunes I, Tolaini M, Kissenpfennig A, Iwashiro M, Kuribayashi K, Malissen B, Hasenkrug K, Kassiotis G. 2008. Retrovirus-specificity of regulatory t cells is neither present nor required in preventing retrovirus-induced bone marrow immune pathology. Immunity, 29: 782-794.
- . Barber D L, Wherry E J, Masopust D, Zhu B, Allison J P, Sharpe A H, Freeman G J, Ahmed R. 2006. Restoring function in exhausted cd8 t cells during chronic viral infection. Nature, 439: 682-687.
- . Barron L, Dooms H, Hoyer K K, Kuswanto W, Hofmann J, O'Gorman W E, Abbas A K. 2010. Cutting edgeh: Mechanisms of il-2-dependent maintenance of functional regulatory t cells. J Immunol, 185: 6426-6430.
- . Bedoya F, Cheng G S, Leibow A, Zakhary N, Weissler K, Garcia V, Aitken M, Kropf E, Garlick D S, Wherry E J, Erikson J, Caton A J. 2013. Viral antigen induces differentiation of foxp3+ natural regulatory t cells in influenza virus-infected mice. J Immunol, 190: 6115-6125.
- . Blackburn S D, Shin H, Haining W N, Zou T, Workman C J, Polley A, Betts M R, Freeman G J, Vignali D A, Wherry E J. 2009. Coregulation of cd8+ t cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol, 10: 29-37.
- . Cabarrocas J, Cassan C, Magnusson F, Piaggio E, Mars L, Derbinski J, Kyewski B, Gross D A, Salomon B L, Khazaie K, Saoudi A, Liblau R S. 2006. Foxp3+ cd25+ regulatory t cells specific for a neo-self-antigen develop at the double-positive thymic stage. P Nat Acad Sci USA, 103: 8453-8458.
- . Chevalier M F, Weiss L. 2013. The split personality of regulatory t cells in hiv infection. Blood, 121: 29-37.
- . Choi Y, Kappler J W, Marrack P. 1991. A superantigen encoded in the open reading frame of the 3' long terminal repeat of mouse mammary tumour virus. Nature, 350: 203-207.
- . Coquet J M, Ribot J C, Babala N, Middendorp S, van der Horst G, Xiao Y, Neves J F, Fonseca-Pereira D, Jacobs H, Pennington D J, Silva-Santos B, Borst J. 2013. Epithelial and dendritic cells in the thymic medulla promote cd4+foxp3+ regulatory t cell development via the cd27-cd70 pathway. J Exp Med, 210: 715-728.
- . Coutinho A, Caramalho I, Seixas E, Demengeot J. 2005. Thymic commitment of regulatory t cells is a pathway of tcr-dependent selection that isolates repertoires undergoing positive or negative selection. Curr Top Microbiol, 293: 43-71.
- . Dietze K K, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U. 2013. Combining regulatory t cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific cd8(+) t cells and efficiently reduces chronic retroviral loads. PLoS Pathog, 9: e1003798.
- . Dittmer U, He H, Messer R J, Schimmer S, Olbrich A R, Ohlen C, Greenberg P D, Stromnes I M, Iwashiro M, Sakaguchi S, Evans L H, Peterson K E, Yang G, Hasenkrug K J. 2004. Functional impairment of cd8 (+) t cells by regulatory t cells during persistent retroviral infection. Immunity, 20: 293-303.
- . Ebinuma H, Nakamoto N, Li Y, Price D A, Gostick E, Levine B L, Tobias J, Kwok W W, Chang K M. 2008. Identification and in vitro expansion of functional antigen-specific cd25+ foxp3+ regulatory t cells in hepatitis c virus infection. J Virol, 82: 5043-5053.
- . Fontenot J D, Rasmussen J P, Williams L M, Dooley J L, Farr A G, Rudensky A Y. 2005. Regulatory t cell lineage specification by the forkhead transcription factor foxp3. Immunity, 22: 329-341.
- . Francisco L M, Salinas V H, Brown K E, Vanguri V K, Freeman G J, Kuchroo V K, Sharpe A H. 2009. Pd-l1 regulates the development, maintenance, and function of induced regulatory t cells. J Exp Med, 206: 3015-3029.
- . Furuichi Y, Tokuyama H, Ueha S, Kurachi M, Moriyasu F, Kakimi K. 2005. Depletion of cd25+cd4+t cells (tregs) enhances the hbv-specific cd8+ t cell response primed by DNA immunization. World J Gastroentero, 11: 3772-3777.
- . Gottschalk R A, Corse E, Allison J P. 2012. Expression of helios in peripherally induced foxp3+ regulatory t cells. J Immunol, 188: 976-980.
- . Iwashiro M, Messer R J, Peterson K E, Stromnes I M, Sugie T, Hasenkrug K J. 2001. Immunosuppression by cd4+ regulatory t cells induced by chronic retroviral infection. P Nat Acad Sci USA, 98: 9226-9230.
- . Jones R B, Ndhlovu L C, Barbour J D, Sheth P M, Jha A R, Long B R, Wong J C, Satkunarajah M, Schweneker M, Chapman J M, Gyenes G, Vali B, Hyrcza M D, Yue F Y, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht F M, Chun T W, McCune J M, Kaul R, Rini J M, Nixon D F, Ostrowski M A. 2008. Tim-3 expression defines a novel population of dysfunctional t cells with highly elevated frequencies in progressive hiv-1 infection. J Exp Med, 205: 2763-2779.
- . Killebrew J R, Perdue N, Kwan A, Thornton A M, Shevach E M, Campbell D J. 2011. A self-reactive tcr drives the development of foxp3+ regulatory t cells that prevent autoimmune disease. J Immunol, 187: 861-869.
- . Kohm A P, Carpentier P A, Anger H A, Miller S D. 2002. Cutting edge: Cd4+cd25+ regulatory t cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol, 169: 4712-4716.
- . Kryworuchko M, Theze J. 2006. Interleukin-2: From t cell growth and homeostasis to immune reconstitution of hiv patients. Vitam Horm, 74: 531-547.
- . Leavy O. 2013. Regulatory t cells: The thymic medulla -a cradle for treg cell development. Nat Rev Immunol, 13: 304.
- . Li W, Green W R. 2011. Immunotherapy of murine retrovirus-induced acquired immunodeficiency by cd4 t regulatory cell depletion and pd-1 blockade. J Virol, 85: 13342-13353.
- . Lilly F, Steeves R A. 1973. B-tropic friend virus: A host-range pseudotype of spleen focus-forming virus (sffv). Virology, 55: 363-370.
- . Malek T R. 2003. The main function of il-2 is to promote the development of t regulatory cells. J Leukocyte Biol, 74: 961-965.
- . Manigold T, Racanelli V. 2007. T-cell regulation by cd4 regulatory t cells during hepatitis b and c virus infections: Facts and controversies. Lancet Infect Dis, 7: 804-813.
- . Mills K H. 2004. Regulatory t cells: Friend or foe in immunity to infection?. Nat Rev Immunol, 4: 841-855.
- . Myers L, Joedicke J J, Carmody A B, Messer R J, Kassiotis G, Dudley J P, Dittmer U, Hasenkrug K J. 2013. Il-2-independent and tnf-alpha-dependent expansion of vbeta5+ natural regulatory t cells during retrovirus infection. J Immunol, 190: 5485-5495.
- . Nilsson J, Boasso A, Velilla P A, Zhang R, Vaccari M, Franchini G, Shearer G M, Andersson J, Chougnet C. 2006. Hiv-1-driven regulatory t-cell accumulation in lymphoid tissues is associated with disease progression in hiv/aids. Blood, 108: 3808-3817.
- . Palmer B E, Neff C P, Lecureux J, Ehler A, Dsouza M, Remling-Mulder L, Korman A J, Fontenot A P, Akkina R. 2013. In vivo blockade of the pd-1 receptor suppresses hiv-1 viral loads and improves cd4+ t cell levels in humanized mice. J Immunol, 190: 211-219.
- . Piersma S J, van der Hulst J M, Kwappenberg K M, Goedemans R, van der Minne C E, van der Burg S H. 2010. Influenza matrix 1-specific human cd4+ foxp3+ and foxp3 (-) regulatory t cells can be detected long after viral clearance. Eur J Immunol, 40: 3064-3074.
- . Presicce P, Orsborn K, King E, Pratt J, Fichtenbaum C J, Chougnet C A. 2011. Frequency of circulating regulatory t cells increases during chronic hiv infection and is largely controlled by highly active antiretroviral therapy. PloS One, 6: e28118.
- . Punkosdy G A, Blain M, Glass D D, Lozano M M, O'Mara L, Dudley J P, Ahmed R, Shevach E M. 2011. Regulatory t-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens. P Nat Acad Sci USA, 108: 3677-3682.
- . Robertson S J, Messer R J, Carmody A B, Hasenkrug K J. 2006. In vitro suppression of cd8+ t cell function by friend virus-induced regulatory t cells. J Immunol, 176: 3342-3349.
- . Sadlack B, Merz H, Schorle H, Schimpl A, Feller A C, Horak I. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell, 75: 253-261.
- . Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 1995. Immunologic self-tolerance maintained by activated t cells expressing il-2 receptor alpha-chains (cd25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.. J Immunol, 155: 1151-1164.
- . Sakuishi K, Ngiow S F, Sullivan J M, Teng M W, Kuchroo V K, Smyth M J, Anderson A C. 2013. Tim3foxp3 regulatory t cells are tissue-specific promoters of t-cell dysfunction in cancer. Oncoimmunology, 2: e23849.
- . Sanchez A M, Zhu J, Huang X, Yang Y. 2012. The development and function of memory regulatory t cells after acute viral infections. J Immunol, 189: 2805-2814.
- . Scheffold A, Huhn J, Hofer T. 2005. Regulation of cd4+cd25+ regulatory t cell activity: It takes (il-) two to tango. Eur J Immunol, 35: 1336-1341.
- . Sugimoto N, Oida T, Hirota K, Nakamura K, Nomura T, Uchiyama T, Sakaguchi S. 2006. Foxp3-dependent and -independent molecules specific for cd25+cd4+ natural regulatory t cells revealed by DNA microarray analysis. Int Immunol, 18: 1197-1209.
- . Suzuki H, Duncan G S, Takimoto H, Mak T W. 1997. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the il-2 receptor beta chain. J Exp Med, 185: 499-505.
- . Taylor A L, Llewelyn M J. 2010. Superantigen-induced proliferation of human cd4+cd25-t cells is followed by a switch to a functional regulatory phenotype. J Immunol, 185: 6591-6598.
- . Thornton A M, Korty P E, Tran D Q, Wohlfert E A, Murray P E, Belkaid Y, Shevach E M. 2010. Expression of helios, an ikaros transcription factor family member, differentiates thymic-derived from peripherally induced foxp3+ t regulatory cells. J Immunol, 184: 3433-3441.
- . Verhagen J, Wraith D C. 2010. Comment on "expression of helios, an ikaros transcription factor family member, differentiates thymic-derived from peripherally induced foxp3+ t regulatory cells". J Immunol, 185: 7129; author reply 7130.
- . Wang H Y, Lee D A, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach E M, Wang R F. 2004. Tumor-specific human cd4+ regulatory t cells and their ligands: Implications for immunotherapy. Immunity, 20: 107-118.
- . Wei W Z, Morris G P, Kong Y C. 2004. Anti-tumor immunity and autoimmunity: A balancing act of regulatory t cells. Cancer Immunol Immun, 53: 73-78.
- . Willerford D M, Chen J, Ferry J A, Davidson L, Ma A, Alt F W. 1995. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity, 3: 521-530.
- . Woodland D, Happ M P, Bill J, Palmer E. 1990. Requirement for cotolerogenic gene products in the clonal deletion of i-e reactive t cells. Science, 247: 964-967.
- . Woodland D L, Blackman M A. 1993. How do t-cell receptors, mhc molecules and superantigens get together?. Immunology Today, 14: 208-212.
- . Yang J H, Zhang Y X, Yu R B, Su C, Sun N X. 2006. cd4+ cd25+ regulatory t cells suppress cd4+ t cell responses in patients with persistent hepatitis c virus infection. Chinese Journal of Internal Medicine, 45: 29-33.
- . Young G R, Ploquin M J, Eksmond U, Wadwa M, Stoye J P, Kassiotis G. 2012. Negative selection by an endogenous retrovirus promotes a higher-avidity cd4+ t cell response to retroviral infection. PLoS Pathog, 8: e1002709.
- . Zelinskyy G, Kraft A R, Schimmer S, Arndt T, Dittmer U. 2006. Kinetics of cd8+ effector t cell responses and induced cd4+ regulatory t cell responses during friend retrovirus infection. Eur J Immunol, 36: 2658-2670.
- . Zelinskyy G, Dietze K K, Husecken Y P, Schimmer S, Nair S, Werner T, Gibbert K, Kershaw O, Gruber A D, Sparwasser T, Dittmer U. 2009. The regulatory t-cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus-specific cytotoxic t-cell response. Blood, 114: 3199-3207.
- . Zhou Q, Munger M E, Highfill S L, Tolar J, Weigel B J, Riddle M, Sharpe A H, Vallera D A, Azuma M, Levine B L, June C H, Murphy W J, Munn D H, Blazar B R. 2010. Program death-1 signaling and regulatory t cells collaborate to resist the function of adoptively transferred cytotoxic t lymphocytes in advanced acute myeloid leukemia. Blood, 116: 2484-2493.